Neogenomics Inc
NEO6.580USD
-3.390-34.00%
Close 04/29, 16:00（ET）Quotes delayed by 15 min
843.20MMarket Cap
LossP/E TTM
More Details of Neogenomics Inc Company
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Company Info
Company codeNEO
Company nameNeogenomics Inc
IPO dateDec 10, 2012
Founded at1998
CEOMr. Antony P. Zook
Number of employees2200
Security typeOrdinary Share
Fiscal year-endDec 10
Address9490 Neogenomics Way
CityFORT MYERS
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33912
Phone12397680600
Websitehttps://neogenomics.com/
Company codeNEO
IPO dateDec 10, 2012
Founded at1998
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey Scott (Jeff) Sherman
Mr. Jeffrey Scott (Jeff) Sherman
Chief Financial Officer
Chief Financial Officer
136.82K
+1.29%
Mr. Warren Stone
Mr. Warren Stone
President, Chief Operating Officer
President, Chief Operating Officer
90.79K
-9.57%
Mr. Stephen Michael Kanovsky
Mr. Stephen Michael Kanovsky
Independent Director
Independent Director
36.09K
--
Ms. Elizabeth Floegel
Ms. Elizabeth Floegel
Independent Director
Independent Director
11.34K
--
Dr. Neil Gunn
Dr. Neil Gunn
Independent Director
Independent Director
11.34K
--
Mr. David B. Perez
Mr. David B. Perez
Independent Director
Independent Director
--
--
Ms. Alicia Olivo
Ms. Alicia Olivo
Executive Vice President, General Counsel & Business Development
Executive Vice President, General Counsel & Business Development
--
--
Ms. Felicia Williams
Ms. Felicia Williams
Independent Director
Independent Director
--
--
Mr. Michael A. Kelly
Mr. Michael A. Kelly
Lead Independent Director
Lead Independent Director
--
--
Mr. Antony P. Zook
Mr. Antony P. Zook
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey Scott (Jeff) Sherman
Mr. Jeffrey Scott (Jeff) Sherman
Chief Financial Officer
Chief Financial Officer
136.82K
+1.29%
Mr. Warren Stone
Mr. Warren Stone
President, Chief Operating Officer
President, Chief Operating Officer
90.79K
-9.57%
Mr. Stephen Michael Kanovsky
Mr. Stephen Michael Kanovsky
Independent Director
Independent Director
36.09K
--
Ms. Elizabeth Floegel
Ms. Elizabeth Floegel
Independent Director
Independent Director
11.34K
--
Dr. Neil Gunn
Dr. Neil Gunn
Independent Director
Independent Director
11.34K
--
Mr. David B. Perez
Mr. David B. Perez
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Clinical Services-Client direct billing
475.44M
71.98%
Clinical Services-Commercial Insurance
99.84M
15.11%
Clinical Services-Medicare and Medicaid
84.60M
12.81%
Clinical Services-Self-Pay
681.00K
0.10%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Clinical Services-Client direct billing
475.44M
71.98%
Clinical Services-Commercial Insurance
99.84M
15.11%
Clinical Services-Medicare and Medicaid
84.60M
12.81%
Clinical Services-Self-Pay
681.00K
0.10%
Shareholder
Update time: Thu, Mar 20
Update time: Thu, Mar 20
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
BlackRock Institutional Trust Company, N.A.
14.49%
The Vanguard Group, Inc.
11.05%
Millennium Management LLC
5.41%
T. Rowe Price Investment Management, Inc.
5.07%
Janus Henderson Investors
4.79%
Other
59.19%
Shareholder Statistics
Shareholder
Proportion
BlackRock Institutional Trust Company, N.A.
14.49%
The Vanguard Group, Inc.
11.05%
Millennium Management LLC
5.41%
T. Rowe Price Investment Management, Inc.
5.07%
Janus Henderson Investors
4.79%
Other
59.19%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
46.65%
Investment Advisor
42.43%
Hedge Fund
9.41%
Research Firm
1.68%
Pension Fund
1.08%
Individual Investor
1.06%
Bank and Trust
0.57%
Sovereign Wealth Fund
0.39%
Family Office
0.02%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
568
133.27M
103.75%
-2.98M
2024Q4
585
127.59M
99.32%
-7.82M
2024Q3
589
129.38M
100.96%
-8.76M
2024Q2
597
131.21M
102.74%
-9.36M
2024Q1
633
132.83M
104.04%
-13.13M
2023Q4
672
130.90M
102.70%
-12.18M
2023Q3
691
124.98M
98.00%
-16.78M
2023Q2
691
121.76M
95.45%
-23.63M
2023Q1
704
120.14M
94.21%
-27.80M
2022Q4
717
116.51M
92.28%
-28.70M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
18.64M
14.51%
+221.10K
+1.20%
Dec 31, 2024
The Vanguard Group, Inc.
14.21M
11.06%
+192.25K
+1.37%
Dec 31, 2024
Millennium Management LLC
6.95M
5.41%
+5.53M
+387.74%
Mar 13, 2025
T. Rowe Price Investment Management, Inc.
6.53M
5.08%
-13.29K
-0.20%
Dec 31, 2024
Janus Henderson Investors
6.17M
4.8%
-438.12K
-6.63%
Dec 31, 2024
Brown Advisory
6.16M
4.79%
-733.08K
-10.64%
Dec 31, 2024
State Street Global Advisors (US)
5.20M
4.05%
+239.91K
+4.84%
Dec 31, 2024
Greenhouse Funds LLLP
4.70M
3.66%
+237.49K
+5.32%
Dec 31, 2024
Macquarie Investment Management
3.81M
2.97%
-12.39K
-0.32%
Dec 31, 2024
Schroder Investment Management North America Inc.
3.80M
2.96%
-419.61K
-9.94%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
SPDR S&P Health Care Services ETF
1.66%
WisdomTree BioRevolution Fund
0.85%
Invesco S&P SmallCap Health Care ETF
0.76%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.51%
First Trust Small Cap Growth AlphaDEX Fund
0.22%
OneAscent Small Cap Core ETF
0.2%
iShares U.S. Healthcare Providers ETF
0.19%
Inspire Small/Mid Cap ESG ETF
0.12%
First Trust Small Cap Core Alphadex Fund
0.12%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.11%
View more
SPDR S&P Health Care Services ETF
Proportion1.66%
WisdomTree BioRevolution Fund
Proportion0.85%
Invesco S&P SmallCap Health Care ETF
Proportion0.76%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.51%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.22%
OneAscent Small Cap Core ETF
Proportion0.2%
iShares U.S. Healthcare Providers ETF
Proportion0.19%
Inspire Small/Mid Cap ESG ETF
Proportion0.12%
First Trust Small Cap Core Alphadex Fund
Proportion0.12%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proportion0.11%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data